Prostatic Neoplasms: Gooren LJ

  Topic:  
Hints · Remembered Topics    
  Start Here  Overview  World Articles  Find Experts  Books & DVDs  Help 
 
Column View Map 2 Articles   Help
A digest of articles written 1999 and later, on the topic "Prostatic Neoplasms," originating from Planet Earth —» Gooren LJ.  Display:  All Citations ·  All Abstracts
1 Guideline ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. 2009

Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. · Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles BioMedical Research Institute, Torrance, CA 90509, USA. · Aging Male. · Pubmed #18763169 No free full text.

This publication has no abstract.

2 Article Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. 2007

Gooren LJ, Behre HM, Saad F, Frank A, Schwerdt S. · Endocrinology/Andrology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands. · Aging Male. · Pubmed #18033626 No free full text.

Abstract: AIM: This study analysed variations between different regions of the world in diagnosing and treating testosterone (T) deficiency. METHODS: Physicians were interviewed in Germany, Spain and the United Kingdom, in Brazil, in Saudi Arabia and South Korea. Items in the survey: 1) reasons/motivation to use or not to use T; 2) what category of patients would not receive T on the basis of these concerns; 3) concerns about prostate pathology in the decision not to provide T treatment; 4) phosphodiesterase type 5 (PDE-5) inhibitors are efficacious, but T treatment makes a comeback. RESULTS: Between 5% and 10% of consulting patients suffered from T deficiency. The fear to induce prostate cancer appeared very powerful. About 68% of physicians associate the use of T more with risks than benefits, more so in Europe than elsewhere. As a result about 35% of hypogonadal men do not receive treatment. The PDE-5 inhibitors are very prominent in the treatment of erectile dysfunction. Of patients suffering from erectile dysfunction, 18% to 29% have T deficiency which is not always diagnosed and treated. CONCLUSION: World-wide physicians require more education on diagnosing T deficiency, on the role of T in erectile dysfunction and the relative safety of testosterone treatment.